| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
|
N Engl J Med
|
2015
|
7.51
|
|
3
|
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
|
J Clin Oncol
|
2008
|
3.58
|
|
4
|
Concern
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
|
Oncologist
|
2003
|
3.36
|
|
5
|
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
|
J Clin Oncol
|
2011
|
2.87
|
|
6
|
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
|
Clin Cancer Res
|
2005
|
2.29
|
|
7
|
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
|
Sci Transl Med
|
2013
|
2.07
|
|
8
|
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
|
Mol Cell Proteomics
|
2004
|
1.76
|
|
9
|
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
|
J Clin Invest
|
2013
|
1.36
|
|
10
|
Targeted therapies for cancer 2004.
|
Am J Clin Pathol
|
2004
|
1.23
|
|
11
|
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
|
Mol Ther
|
2012
|
1.20
|
|
12
|
Central nervous system cancers.
|
J Natl Compr Canc Netw
|
2011
|
1.13
|
|
13
|
Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
|
Clin Cancer Res
|
2009
|
1.12
|
|
14
|
Breast cancer biomarkers and molecular medicine.
|
Expert Rev Mol Diagn
|
2003
|
1.12
|
|
15
|
Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
|
J Immunol
|
2002
|
1.09
|
|
16
|
Melanocyte receptors: clinical implications and therapeutic relevance.
|
Dermatol Clin
|
2007
|
1.01
|
|
17
|
DNA ploidy and cell cycle analysis in breast cancer.
|
Am J Clin Pathol
|
2003
|
0.98
|
|
18
|
HER-2/neu testing in breast cancer.
|
Am J Clin Pathol
|
2003
|
0.95
|
|
19
|
Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization.
|
Arch Ophthalmol
|
2009
|
0.93
|
|
20
|
Hepatic arterial chemoembolization for management of metastatic melanoma.
|
AJR Am J Roentgenol
|
2008
|
0.90
|
|
21
|
Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib.
|
J Clin Oncol
|
2012
|
0.89
|
|
22
|
Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging.
|
Am J Clin Pathol
|
2003
|
0.88
|
|
23
|
Breast cancer biomarkers and molecular medicine: part II.
|
Expert Rev Mol Diagn
|
2004
|
0.88
|
|
24
|
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.
|
J Immunol
|
2012
|
0.87
|
|
25
|
Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.
|
J Biol Chem
|
2008
|
0.87
|
|
26
|
CD40 regulates human dendritic cell-derived IL-7 production that, in turn, contributes to CD8(+) T-cell antigen-specific expansion.
|
Immunol Cell Biol
|
2008
|
0.87
|
|
27
|
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
|
Cancer Chemother Pharmacol
|
2008
|
0.84
|
|
28
|
Oligodendrogliomas in children.
|
J Neurooncol
|
2011
|
0.82
|
|
29
|
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
|
Neuro Oncol
|
2013
|
0.82
|
|
30
|
Biomarkers in melanoma: staging, prognosis and detection of early metastases.
|
Expert Rev Mol Diagn
|
2003
|
0.81
|
|
31
|
Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.
|
Arch Dermatol
|
2002
|
0.81
|
|
32
|
Biomarkers in melanoma: predisposition, screening and diagnosis.
|
Expert Rev Mol Diagn
|
2003
|
0.80
|
|
33
|
Central nervous system cancers.
|
J Natl Compr Canc Netw
|
2008
|
0.79
|
|
34
|
Pharmacogenomics.
|
Adv Anat Pathol
|
2004
|
0.78
|
|
35
|
Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
|
J Cutan Pathol
|
2014
|
0.76
|
|
36
|
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
|
Melanoma Res
|
2017
|
0.75
|